Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Data from Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Joo Ern Ang, Charlie Gourley, C. Bethan Powell, Hilda High, Ronnie Shapira-Frommer, Vincent Castonguay, Jacques De Grève, Tina Atkinson, Timothy A. Yap, Shahneen Sandhu, Susana Banerjee, Lee-may Chen, Michael Friedlander, Bella Kaufman, Amit M. Oza, Ursula A. Matulonis, Louise J. Barber, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, James R. Campbell, Lina Chen, Johann S. de Bono, Martin Gore, Christopher J. Lord, Alan Ashworth, Stan B. Kaye (2023). Data from Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. , DOI: https://doi.org/10.1158/1078-0432.c.6520686.
Preprint147 days agoData from Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Joo Ern Ang, Charlie Gourley, C. Bethan Powell, Hilda High, Ronnie Shapira-Frommer, Vincent Castonguay, Jacques De Grève, Tina Atkinson, Timothy A. Yap, Shahneen Sandhu, Susana Banerjee, Lee-may Chen, Michael Friedlander, Bella Kaufman, Amit M. Oza, Ursula A. Matulonis, Louise J. Barber, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, James R. Campbell, Lina Chen, Johann S. de Bono, Martin Gore, Christopher J. Lord, Alan Ashworth, Stan B. Kaye (2023). Data from Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. , DOI: https://doi.org/10.1158/1078-0432.c.6520686.v1.
Preprint147 days agoSupplementary Table 1 from Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Joo Ern Ang, Charlie Gourley, C. Bethan Powell, Hilda High, Ronnie Shapira-Frommer, Vincent Castonguay, Jacques De Grève, Tina Atkinson, Timothy A. Yap, Shahneen Sandhu, Susana Banerjee, Lee-may Chen, Michael Friedlander, Bella Kaufman, Amit M. Oza, Ursula A. Matulonis, Louise J. Barber, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, James R. Campbell, Lina Chen, Johann S. de Bono, Martin Gore, Christopher J. Lord, Alan Ashworth, Stan B. KayeSupplementary Table 1 from Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. , DOI: https://doi.org/10.1158/1078-0432.22446225.
Dataset141 days agoSupplementary Table 1 from Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Joo Ern Ang, Charlie Gourley, C. Bethan Powell, Hilda High, Ronnie Shapira-Frommer, Vincent Castonguay, Jacques De Grève, Tina Atkinson, Timothy A. Yap, Shahneen Sandhu, Susana Banerjee, Lee-may Chen, Michael Friedlander, Bella Kaufman, Amit M. Oza, Ursula A. Matulonis, Louise J. Barber, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, James R. Campbell, Lina Chen, Johann S. de Bono, Martin Gore, Christopher J. Lord, Alan Ashworth, Stan B. KayeSupplementary Table 1 from Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. , DOI: https://doi.org/10.1158/1078-0432.22446225.v1.
Dataset141 days ago